《大行報告》匯豐研究升敏華(01999.HK)評級至「買入」 目標價上調至18.3元
匯豐研究發表報告,指敏華(01999.HK)2021財年上半年收入及純利分別按年增長18.7%及6.2%,經常性純利按年增長14.9%。9月底止的門店數目按年增加30%,相信未來1至2年會繼續增加店舖數目。
為了反映公司2021財年上半年的業績,將2021至2023財年的收入預測分別上調4.4%、4.6%及4.7%,並將2022及2023財年的銷售開支比率下調。因此,2021至2023財年的純利預測分別上調7.9%、10.6%及15.8%。該行預期2021至2023年的純利年複合增長率為20%。目標價由原來的11.6元上調至18.3元,投資評級由「持有」調高至「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.